Edwards Lifesciences Corp Cash Flow Conversion Efficiency
Edwards Lifesciences Corp cash flow conversion efficiency. Based on the latest financial reports, Edwards Lifesciences Corp (EW) has a cash flow conversion efficiency ratio of 0.061x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($651.90 Million) by net assets ($10.72 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Edwards Lifesciences Corp (1999–2025)
Cash flow conversion efficiency of Edwards Lifesciences Corp from 1999 to 2025. This chart illustrates how Edwards Lifesciences Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View EW share price today for real-time trading data and today's change.
Edwards Lifesciences Corp Cash Flow Conversion Ratio Explained
Edwards Lifesciences Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Edwards Lifesciences Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Edwards Lifesciences Corp ranked by their cash flow conversion efficiency. Also see EW company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
L3Harris Technologies Inc
NYSE:LHX
|
0.042x |
|
Thomson Reuters Corp
TO:TRI
|
0.083x |
|
Infosys Limited
NSE:INFY
|
0.109x |
|
Vale S.A.
SA:VALE3
|
0.083x |
|
Constellation Software Inc.
TO:CSU
|
0.167x |
|
Deutsche Bank Aktiengesellschaft
F:DBK
|
-0.250x |
|
WuXi AppTec Co Ltd
SHG:603259
|
0.070x |
|
Thales S.A.
PA:HO
|
0.113x |
Annual Cash Flow Conversion Efficiency for Edwards Lifesciences Corp (1999–2025)
The table below shows the annual cash flow conversion efficiency of Edwards Lifesciences Corp from 1999 to 2025. Review EW free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.34 Billion | $1.60 Billion | 0.154x | +186.34% |
| 2024-12-31 | $10.06 Billion | $542.30 Million | 0.054x | -59.58% |
| 2023-12-31 | $6.72 Billion | $895.80 Million | 0.133x | -36.45% |
| 2022-12-31 | $5.81 Billion | $1.22 Billion | 0.210x | -29.32% |
| 2021-12-31 | $5.84 Billion | $1.73 Billion | 0.297x | +28.77% |
| 2020-12-31 | $4.57 Billion | $1.05 Billion | 0.230x | -18.93% |
| 2019-12-31 | $4.15 Billion | $1.18 Billion | 0.284x | -3.66% |
| 2018-12-31 | $3.14 Billion | $926.80 Million | 0.295x | -11.68% |
| 2017-12-31 | $2.99 Billion | $1.00 Billion | 0.334x | +24.24% |
| 2016-12-31 | $2.62 Billion | $704.40 Million | 0.269x | +22.47% |
| 2015-12-31 | $2.50 Billion | $549.70 Million | 0.220x | -52.92% |
| 2014-12-31 | $2.19 Billion | $1.02 Billion | 0.467x | +53.88% |
| 2013-12-31 | $1.56 Billion | $472.70 Million | 0.303x | +19.98% |
| 2012-12-31 | $1.48 Billion | $373.80 Million | 0.253x | +7.49% |
| 2011-12-31 | $1.34 Billion | $314.50 Million | 0.235x | +22.32% |
| 2010-12-31 | $1.31 Billion | $251.40 Million | 0.192x | +34.61% |
| 2009-12-31 | $1.16 Billion | $165.30 Million | 0.143x | -18.11% |
| 2008-12-31 | $878.80 Million | $153.20 Million | 0.174x | -30.75% |
| 2007-12-31 | $835.00 Million | $210.20 Million | 0.252x | -18.26% |
| 2006-12-31 | $749.40 Million | $230.80 Million | 0.308x | +55.34% |
| 2005-12-31 | $690.00 Million | $136.80 Million | 0.198x | -31.05% |
| 2004-12-31 | $628.10 Million | $180.60 Million | 0.288x | +49.32% |
| 2003-12-31 | $635.10 Million | $122.30 Million | 0.193x | -13.87% |
| 2002-12-31 | $539.40 Million | $120.60 Million | 0.224x | +1.61% |
| 2001-12-31 | $459.00 Million | $101.00 Million | 0.220x | -29.33% |
| 2000-12-31 | $440.00 Million | $137.00 Million | 0.311x | +116.54% |
| 1999-12-31 | $1.22 Billion | $176.00 Million | 0.144x | -- |
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to t… Read more